Alpine Immune Sciences(ALPN) - 2022 Q2 - Quarterly Report

Financial Performance - The company reported a net loss of $18.1 million for Q2 2022, compared to a net loss of $11.0 million for Q2 2021, indicating a year-over-year increase in losses [64]. - Net loss for the three months ended June 30, 2022, was $18.1 million, an increase of $7.1 million (64.4%) from a net loss of $11.0 million in the same period of 2021 [84]. - Total operating expenses for the six months ended June 30, 2022, were $42.9 million, an increase of $11.3 million (35.7%) from $31.6 million in the same period of 2021 [91]. - The company has incurred operating losses since inception and expects to continue significant expenses and losses for the foreseeable future [106]. Cash and Investments - Total cash, cash equivalents, restricted cash, and investments as of June 30, 2022, amounted to $201.2 million [64]. - Cash, cash equivalents, restricted cash, and investments totaled $201.2 million as of June 30, 2022 [97]. - Net cash used in operating activities for the six months ended June 30, 2022, was $10.6 million, a decrease from $30.7 million in the same period of 2021 [102]. - Net cash used in investing activities was $31.2 million for the six months ended June 30, 2022, primarily for net purchases of investments [103]. - The company had $5.8 million in remaining principal balance under its 2019 term loan agreement as of June 30, 2022 [100]. Research and Development - Acazicolcept (ALPN-101) is currently in a Phase 2 study for moderate-to-severe systemic lupus erythematosus (SLE), with $105.0 million received in upfront and milestone payments from AbbVie [59]. - ALPN-303 is in a Phase 1 study, with initial clinical data from basket trials expected in the second half of 2023 [59]. - Davoceticept (ALPN-202) has shown tumor volume reduction in 23% of evaluable participants in a Phase 1 study, with preliminary data from expansion cohorts anticipated in the second half of 2023 [62]. - The company expects research and development expenses to increase in the foreseeable future as it continues to develop its platform and product candidates [75]. - Total direct research and development expenses for Q2 2022 were $9.0 million, an increase from $8.3 million in Q2 2021 [75]. - Total research and development expenses for the first half of 2022 were $33.9 million, compared to $25.1 million for the same period in 2021 [75]. - Indirect research and development expenses increased to $8.5 million in Q2 2022 from $6.3 million in Q2 2021 [75]. - Research and development expenses increased by $3.0 million (20.2%) to $17.6 million for the three months ended June 30, 2022, primarily due to clinical trial activities and personnel-related expenses [86]. Collaboration Agreements - The company has raised an aggregate of $418.1 million since inception, with $185.6 million from common stock sales and $139.2 million from collaboration agreements [64]. - An exclusive collaboration agreement with Horizon Therapeutics includes an upfront payment of $25.0 million and potential future payments of up to $1.5 billion [59]. - AbbVie Agreement includes a nonrefundable upfront payment of $60.0 million and potential cash payments up to $75.0 million upon achieving predefined development milestones [66]. - Revenue recognized from the AbbVie Agreement was $4.6 million for Q2 2022, compared to $7.2 million for Q2 2021, and $10.5 million for the first half of 2022, compared to $10.4 million for the same period in 2021 [68]. - Horizon Agreement resulted in an upfront payment of $25.0 million and an equity investment of $15.0 million, with potential future success-based payments of up to $1.5 billion [69]. - Revenue recognized from the Horizon Agreement was $0.6 million for Q2 2022 and $8.3 million for the first half of 2022 [69]. - Collaboration revenue for the three months ended June 30, 2022, was $5.3 million, a decrease of $1.9 million (35.5%) compared to $7.2 million in the same period of 2021 [84]. - For the six months ended June 30, 2022, collaboration revenue was $18.9 million, an increase of $8.5 million (81.8%) compared to $10.4 million in the same period of 2021 [91]. Future Outlook - The company expects to incur significant expenses and operating losses for several years as it continues clinical trials and research and development efforts [64]. - Future revenue is expected to fluctuate based on collaboration and licensing agreements, with potential milestone payments from partners like AbbVie and Horizon [65]. - Future capital requirements are difficult to forecast and will depend on various factors, including the number of product candidates pursued and the costs of clinical trials [106]. - The company anticipates needing to finance cash needs through equity or debt financings and collaboration agreements, which may dilute existing stockholders' ownership [106]. Lease and Tax Provisions - The annual base rent for the office and laboratory space is $1.7 million for the first year, increasing by 3.0% each year thereafter [107]. - A tenant improvement allowance of $5.4 million is included in the base rent, with an additional maximum allowance of $1.8 million amortized over the lease term [107]. - An estimated current foreign income tax provision of $1.3 million has been recorded for expected repayments related to research and development expenditures [108]. - The increase in income tax expense for the six months ended June 30, 2022, was $1.7 million, primarily due to a cumulative change in foreign income tax provision [96]. - The company is not required to provide quantitative and qualitative disclosures about market risk as a "smaller reporting company" [109].